Teva Pharms Usa Drug Patent Portfolio
Teva Pharms Usa owns 1 orange book drug protected by 13 US patents Given below is the list of Teva Pharms Usa's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8232250 | Low frequency glatiramer acetate therapy | 19 Aug, 2030 | Active |
| US8399413 | Low frequency glatiramer acetate therapy | 19 Aug, 2030 | Active |
| US8969302 | Low frequency glatiramer acetate therapy | 19 Aug, 2030 | Active |
| US9155776 | Low frequency glatiramer acetate therapy | 19 Aug, 2030 | Active |
| US9402874 | Low frequency glatiramer acetate therapy | 19 Aug, 2030 | Active |
| US5981589 | Copolymer-1 improvements in compositions of copolymers | 24 May, 2014 | Expired |
| US6054430 | Copolymer-1 improvements in compositions of copolymers | 24 May, 2014 | Expired |
| US6342476 | Copolymer-1 improvements in compositions of copolymers | 24 May, 2014 | Expired |
| US6362161 | Copolymer-1 improvements on compositions of copolymers | 24 May, 2014 | Expired |
| US6620847 | Copolymer-1 improvements in compositions of copolymers | 24 May, 2014 | Expired |
| US6939539 | Copolymer-1 improvements in compositions of copolymers | 24 May, 2014 | Expired |
| US7199098 | Copolymer-1 improvements in compositions of copolymers | 24 May, 2014 | Expired |
| US8367605 | Copolymer-1 improvements in compositions of copolymers | 24 May, 2014 | Expired |
Latest Legal Activities on Teva Pharms Usa's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Teva Pharms Usa.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 24 Jan, 2024 | US9402874 |
|
Expire Patent
Critical
| 10 Apr, 2023 | US8969302 |
|
Case Docketed to Examiner in GAU
Critical
| 18 May, 2021 | US8969302 |
|
Case Docketed to Examiner in GAU
Critical
| 18 May, 2021 | US8232250 |
|
Case Docketed to Examiner in GAU
Critical
| 18 May, 2021 | US8399413 |
|
Maintenance Fee Reminder Mailed
Critical
| 09 Nov, 2020 | US8399413 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Jul, 2020 | US8367605 |
|
Maintenance Fee Reminder Mailed
Critical
| 23 Mar, 2020 | US8232250 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Jan, 2020 | US9402874 |
|
Expire Patent
Critical
| 18 Nov, 2019 | US9155776 |
| Review Certificate Mailed | 20 Jun, 2019 | US8969302 |
| Review Certificate Mailed | 20 Jun, 2019 | US8399413 |
| Review Certificate Mailed | 18 Jun, 2019 | US8232250 |
|
Maintenance Fee Reminder Mailed
Critical
| 03 Jun, 2019 | US9155776 |
| Review Certificate | 28 May, 2019 | US8399413 |
Teva Pharms Usa's Drug Patent Litigations
Teva Pharms Usa's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Feb 16, 2016, against patent number US9155776. The petitioner Mylan Pharmaceuticals Inc., challenged the validity of this patent, with Yeda Research and Development Co. Ltd. as the respondent. Click below to track the latest information on how companies are challenging Teva Pharms Usa's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9155776 | November, 2016 |
Terminated
(02 May, 2017)
| Yeda Research & Development Co., Ltd. et al. | Mylan Pharmaceuticals Inc. et al. |
| US9155776 | July, 2016 |
Terminated
(13 Oct, 2016)
| YEDA RESEARCH & DEVELOPMENT CO., LTD. | Amneal Pharmaceuticals LLC et al. |
| US8969302 | March, 2015 |
FWD Entered
(01 Sep, 2016)
| Yeda Research & Development Co., Ltd. | Mylan Pharmaceuticals Inc. |
| US8969302 | September, 2015 |
FWD Entered
(01 Sep, 2016)
| YEDA RESEARCH & DEVELOPMENT CO. LTD. | Amneal Pharmaceuticals LLC |
| US8232250 | February, 2015 |
FWD Entered
(24 Aug, 2016)
| Yeda Research and Development Co. Ltd. | Mylan Pharmaceuticals Inc. |
| US8232250 | September, 2015 |
Final Written Decision
(24 Aug, 2016)
| Yeda Research & Development Co., Ltd. et al. | Amneal Pharmaceuticals LLC |
| US8399413 | February, 2015 |
FWD Entered
(24 Aug, 2016)
| Yeda Research and Development Co. Ltd. | Mylan Pharmaceuticals Inc. |
| US8399413 | September, 2015 |
FWD Entered
(24 Aug, 2016)
| YEDA RESEARCH & DEVELOPMENT CO. LTD. | Amneal Pharmaceuticals LLC |
| US9155776 | February, 2016 |
Terminated-Denied
(15 Aug, 2016)
| Yeda Research and Development Co. Ltd. | Mylan Pharmaceuticals Inc. |
Teva Pharms Usa's Family Patents
Teva Pharms Usa Drug List
Given below is the complete list of Teva Pharms Usa's drugs and the patents protecting them.
1. Copaxone
Copaxone is protected by 13 patents, out of which 8 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8232250 | Low frequency glatiramer acetate therapy |
19 Aug, 2030
(5 years from now)
| Active |
| US8399413 | Low frequency glatiramer acetate therapy |
19 Aug, 2030
(5 years from now)
| Active |
| US8969302 | Low frequency glatiramer acetate therapy |
19 Aug, 2030
(5 years from now)
| Active |
| US9155776 | Low frequency glatiramer acetate therapy |
19 Aug, 2030
(5 years from now)
| Active |
| US9402874 | Low frequency glatiramer acetate therapy |
19 Aug, 2030
(5 years from now)
| Active |
| US5981589 | Copolymer-1 improvements in compositions of copolymers |
24 May, 2014
(10 years ago)
| Expired |
| US6054430 | Copolymer-1 improvements in compositions of copolymers |
24 May, 2014
(10 years ago)
| Expired |
| US6342476 | Copolymer-1 improvements in compositions of copolymers |
24 May, 2014
(10 years ago)
| Expired |
| US6362161 | Copolymer-1 improvements on compositions of copolymers |
24 May, 2014
(10 years ago)
| Expired |
| US6620847 | Copolymer-1 improvements in compositions of copolymers |
24 May, 2014
(10 years ago)
| Expired |
| US6939539 | Copolymer-1 improvements in compositions of copolymers |
24 May, 2014
(10 years ago)
| Expired |
| US7199098 | Copolymer-1 improvements in compositions of copolymers |
24 May, 2014
(10 years ago)
| Expired |
| US8367605 | Copolymer-1 improvements in compositions of copolymers |
24 May, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Copaxone's drug page